SCHEMBL69754

SCHEMBL69754

CN1CCC(=O)c2ccccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.46
LMNA P02545 3/20 0.45
RAB9A P51151 2/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 3/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 4/20 0.42
TP53 P04637 2/20 0.42
CES1 P23141 2/20 0.42
TTR P02766 1/20 0.42
BCHE P06276 1/20 0.41
SRD5A1 P18405 1/20 0.40
EGFR P00533 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
SLC6A4 P31645 1/20 0.40
HRH1 P35367 1/20 0.40
CYP2A6 P11509 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14408830 0.89 MEN1 (0.50) NOTUMLMNARAB9AHTTKMT2A
SCHEMBL29960722 0.89 MEN1 (0.50) NOTUMLMNARAB9AHTTKMT2A
SCHEMBL29617197 0.80 SETD7 (0.37) NOTUMLMNARAB9AHTTKMT2A
SCHEMBL1253936 0.79 RAB9A (0.47) NOTUMLMNARAB9AHTTKMT2A
SCHEMBL6366299 0.79 NOTUM (0.58) NOTUMLMNAHTTKMT2AMEN1
SCHEMBL30776885 0.79 NOTUM (0.58) NOTUMLMNAHTTKMT2AMEN1
SCHEMBL13024432 0.78 CES1 (0.48) LMNAKMT2AALDH1A1TP53CES1
SCHEMBL16844669 0.76 SETD7 (0.37) LMNAHTTKMT2AMEN1ALDH1A1
SCHEMBL2616326 0.76 SETD7 (0.47) NOTUMLMNARAB9AKMT2AMEN1
SCHEMBL10246639 0.76 LMNA (0.45) NOTUMLMNARAB9AHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1434585-A1 ALKYNE MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2004-07-07 EP claimed
WO-2003032999-A1 ALKYNE MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2003-04-24 WO claimed
CN-119798018-A Synthesis method of benzo cyclic ketone compound alpha-site dichloro substitution 浙江大学 2025-04-11 CN disclosed
EP-4446310-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND Asahi Kasei Kabushiki Kaisha (JP) 2024-10-16 EP disclosed
CN-118382612-A Method for producing blocked isocyanate compound and method for producing isocyanate compound 旭化成株式会社 2024-07-23 CN disclosed
EP-3725787-B1 PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS REGENACY PHARMACEUTICALS INC (US) 2023-11-29 EP disclosed
US-20230348389-A1 PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS REGENACY PHARMACEUTICALS LLC (US) 2023-11-02 US disclosed
US-20230348389-A1 PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS REGENACY PHARMACEUTICALS LLC (US) 2023-11-02 US disclosed
US-11702389-B2 Piperidine derivatives as HDAC1/2 inhibitors REGENACY PHARMACEUTICALS, LLC (US) 2023-07-18 US disclosed
US-11702389-B2 Piperidine derivatives as HDAC1/2 inhibitors REGENACY PHARMACEUTICALS, LLC (US) 2023-07-18 US disclosed
WO-2023106377-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND 旭化成株式会社 2023-06-15 WO disclosed
WO-2004007024-A1 COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB WARNER-LAMBERT COMPANY LLC (US) 2004-01-22 WO disclosed
US-20030165733-A1 Nonaqueous electrolyte solution and secondary battery employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2003-09-04 US disclosed
EP-1317013-A1 NON-AQUEOUS ELECTROLYTE AND SECONDARY CELL USING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2003-06-04 EP disclosed
WO-2003032999-A1 ALKYNE MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2003-04-24 WO disclosed
US-5006544-A 5-hydroxytryptamine antagonist for psychological and gastrointestinal disorders; anxiolytic agents GLAXO GROUP LIMITED (GB) 1991-04-09 US disclosed
EP-0364274-A1 Imidazole derivatives GLAXO GROUP LIMITED (GB) 1990-04-18 EP disclosed
US-4273775-A PREVENTION OF OCULAR AND NEURITIC, DIABETIS-ASSOCIATED COMPLICATIONS PFIZER INC. (US) 1981-06-16 US disclosed
EP-0021704-A1 Spiro-hydantoin derivatives, process for their preparation and pharmaceutical compositions thereof PFIZER INC. (US) 1981-01-07 EP disclosed
US-4235911-A TETRAHYDROQUINOLINE-DERIVED SPIRO-HYDANTOINS, CONTROL OF DIABETIC COMPLICATIONS PFIZER INC. (US) 1980-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702389-B2 Piperidine derivatives as HDAC1/2 inhibitors HDAC1, HDAC2, HDAC10 NOTUM 3049/4885LMNA 2773/4885RAB9A 2546/4885
US-20230348389-A1 PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS HDAC1, HDAC2, HDAC10 NOTUM 3049/4885LMNA 2773/4885RAB9A 2546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.